Elekta AB
1EKTA
Company Profile
Business description
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
Contact
Hagaplan 4
Box 7593
Stockholm11368
SWET: +46 858725400
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 April 2027
Employees
4,438
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,980.50 | 31.60 | -0.35% |
| CAC 40 | 8,129.66 | 72.42 | -0.88% |
| DAX 40 | 24,447.04 | 216.57 | -0.88% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,195.35 | 81.60 | -0.79% |
| HKSE | 26,396.18 | 230.10 | -0.86% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,713.65 | 120.19 | -0.19% |
| NZX 50 Index | 13,175.13 | 95.48 | -0.72% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,744.40 | 36.40 | -0.41% |
| SSE Composite Index | 4,179.95 | 0.14 | -0.00% |